# Alnylam to Webcast Presentations at Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676
Ticker: ALNY
Company: Alnylam Pharmaceuticals, Inc.
Source: Alnylam Pharmaceuticals, Inc.
Published: 2026-07-09 18:25 EST
Original Source URL: https://investors.alnylam.com/press-releases
## Summary

May 07, 2026 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present compan...

## Article Body
May 07, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada

Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida.

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events . Replays will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

View source version on businesswire.com : https://www.businesswire.com/news/home/20260507963806/en/

Alnylam Pharmaceuticals, Inc. Christine Akinc

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.
## Recent Company News
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 12:00 EST — [Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi](https://biopharmsignal.com/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-p-508fc61d) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — [Alnylam to Webcast Presentations at Upcoming Investor Conferences](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris](https://biopharmsignal.com/news/ALNY/new-data-analyses-presented-at-heart-failure-2026-demonstrate-robust-and-consist-d10768e9) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — [Alnylam Issues 2025 Corporate Responsibility Report](https://biopharmsignal.com/news/ALNY/alnylam-issues-2025-corporate-responsibility-report-62023cfe) — Source: Alnylam Pharmaceuticals, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)